Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9BYT1

UPID:
S17A9_HUMAN

ALTERNATIVE NAMES:
Solute carrier family 17 member 9; Vesicular nucleotide transporter

ALTERNATIVE UPACC:
Q9BYT1; B3KTF2; Q5W198; Q8TB07; Q8TBP4; Q8TEL5; Q9BYT0; Q9BYT2

BACKGROUND:
SLC17A9, known for its critical function as a Voltage-gated purine nucleotide uniporter, is essential for the transport of vital nucleotides like ATP, ADP, and GTP into lysosomes and secretory vesicles. This activity is fundamental for maintaining ATP levels necessary for the proper function of ATP-dependent proteins in these organelles, thereby playing a significant role in cellular energy homeostasis and the regulation of exocytosis processes.

THERAPEUTIC SIGNIFICANCE:
The association of SLC17A9 with Porokeratosis 8, a condition characterized by abnormal skin keratinization and increased risk of squamous cell carcinomas, highlights its potential as a therapeutic target. Exploring the mechanisms by which SLC17A9 influences this skin disorder could lead to innovative treatments that address both the keratinization defects and the heightened cancer risk.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.